TGFB1 and cancer: In summary, these findings highlight that the regulation of PD-L1 expression on cancer cells may account for the immunosuppressive activity of TGF-β, providing a rationale, as discussed above, for double blockade of PD-1 and TGF-β signaling in anticancer therapy.